DOI QR코드

DOI QR Code

Epirubicin Inhibits Soluble CD25 Secretion by Treg Cells Isolated from Diffuse Large B-cell Lymphoma Patients

  • Li, Lan-Fang (Department of Lymphoma, Sino-US Center of Lymphoma and Leukemia, Tianjin Medical University Cancer Hospital and Institute) ;
  • Wang, Hua-Qing (Department of Lymphoma, Sino-US Center of Lymphoma and Leukemia, Tianjin Medical University Cancer Hospital and Institute) ;
  • Liu, Xian-Ming (Department of Lymphoma, Sino-US Center of Lymphoma and Leukemia, Tianjin Medical University Cancer Hospital and Institute) ;
  • Ren, Xiu-Bao (Department of Immunology, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Hospital and Institute)
  • Published : 2013.03.30

Abstract

Objective: To investigate the effect of epirubicin on soluble CD25 (sCD25) secretion by CD4+CD25+ regulatory T (Treg) cells isolated from diffuse large B-cell lymphoma (DLBCL) patients. Methods: Treg cells were isolated from the peripheral blood mononuclear cells isolated from the newly diagnosed DBLCL patients. The concentration of sCD25 in the supernatant was determined with a commercial sCD25 (IL-2R) enzyme-linked immunosorbent assay (ELISA) kit. The fluorescence intensity of CD25 was detected by flow cytometry. Results: Cell survival rate was significantly decreased along with the increase of epirubicin concentration after treatment for 24 h. There was also a significant difference in the concentration of sCD25 between the epirubicin group and the control group (P<0.01). A positive correlation between the Treg cells survival rate and the concentration of sCD25 was detected (r=0.993, P<0.01). When equal numbers of CD4+CD25+ Treg cells of the epirubicin group and the control group were cultured for another 24 h without epirubicin the CD25 fluorescence intensity on the surface of Treg cells was obviously higher in the epirubicin group than that in the control group (P<0.01), while the sCD25 concentration in the supernatant in the epirubicin group was significantly lower than that in the control group (P<0.05). Conclusion: Epirubicin may improve the body's immune functions by inhibiting the sCD25 secretion by Treg cells in DLBCL patients.

References

  1. Bien E, Balcerska A (2008). Serum soluble interleukin 2 receptor alpha in human cancer of adults and children: a review. Biomarkers, 13, 1-26. https://doi.org/10.1080/13547500701674063
  2. Chang DK, Sui J, Geng S, et al (2012). Humanization of an anti-CCR4 antibody that kills cutaneous T-cell lymphoma cells and abrogates suppression by T-regulatory cells. Mol Cancer Ther, 11, 2451-61. https://doi.org/10.1158/1535-7163.MCT-12-0278
  3. Fan R, Zhang LY, Wang H, et al (2012). Multicentre hospitalbased case-control study of diffuse large B-cell lymphoma in Shanghai, China. Asian Pac J Cancer Prev, 13, 3329-34. https://doi.org/10.7314/APJCP.2012.13.7.3329
  4. Felcht M, Heck M, Weiss C, et al (2012). Expression of the T-cell regulatory marker FOXP3 in primary cutaneous large B-cell lymphoma tumour cells. Br J Dermatol, 167, 348-58. https://doi.org/10.1111/j.1365-2133.2012.10987.x
  5. Goto H, Tsurumi H, Takemura M, et al (2005). Serum-soluble interleukin-2 receptor (sIL-2R) level determines clinical outcome in patients with aggressive non-Hodgkin's lymphoma: in combination with the International Prognostic Index. J Cancer Res Clin Oncol, 131, 73-9. https://doi.org/10.1007/s00432-004-0600-9
  6. Ichihara F, Kono K, Takahashi A, et al (2003). Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers. Clin Cancer Res, 9, 4404-8.
  7. Lindqvist CA, Christiansson LH, Simonsson B, et al (2010). T regulatory cells control T-cell proliferation partly by the release of soluble CD25 in patients with B-cell malignancies. Immunology, 131, 371-6. https://doi.org/10.1111/j.1365-2567.2010.03308.x
  8. Liu Y, Zeng L, Zhang S, et al (2013). Identification of differentially expressed proteins in chemotherapy-sensitive and chemotherapy-resistant diffuse large B cell lymphoma by proteomic methods. Med Oncol, 30, 528. https://doi.org/10.1007/s12032-013-0528-5
  9. Liyanage UK, Moore TT, Joo HG, et al (2002). Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol, 169, 2756-61. https://doi.org/10.4049/jimmunol.169.5.2756
  10. Ormandy LA, Hillemann T, Wedemeyer H, et al (2005). Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. Cancer Res, 65, 2457-64. https://doi.org/10.1158/0008-5472.CAN-04-3232
  11. Sakaguchi S (2000). Regulatory T cells: key controllers of immunologic self-tolerance. Cell, 101, 455-8. https://doi.org/10.1016/S0092-8674(00)80856-9
  12. Woo EY, Chu CS, Goletz TJ, et al (2001). Regulatory CD4(+) CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res, 61, 4766-72.

Cited by

  1. Epirubicin, Identified Using a Novel Luciferase Reporter Assay for Foxp3 Inhibitors, Inhibits Regulatory T Cell Activity vol.11, pp.6, 2016, https://doi.org/10.1371/journal.pone.0156643